Anti cd20 antibody

Manufactured by BioLegend

Sourced in United States

The Anti-CD20 antibody is a laboratory reagent used in research applications. It is a monoclonal antibody that specifically binds to the CD20 cell surface antigen, which is expressed on B cells. The antibody can be used for the identification and isolation of CD20-positive cells in various experimental settings.

Automatically generated - may contain errors

Lab products found in correlation

Smi 4a, by Selleck Chemicals (1 mentions) Isotype control antibody, by BioLegend (1 mentions) Anti cd8 antibody, by BioXCell (1 mentions) Sa271g2, by BioLegend (1 mentions) Buv395 conjugated anti mouse cd8b antibodies, by BD (1 mentions) Apc conjugated anti mouse cd3, by BD (1 mentions)

Spelling variants of this product

Anti-CD20 (8 citations) Anti-mouse CD20 antibody (2 citations)

3 protocols using anti cd20 antibody

Pharmacological Interventions for EAU

Check if the same lab product or an alternative is used in the 5 most similar protocols

The mice were intravenously injected twice weekly with BZ (n = 6; 0.75 mg/kg; Selleck Chemicals, Houston, TX, USA) or an equivalent volume of vehicle control (n = 6; PBS) for 2 weeks^{55 (link)}.
Mice were orally treated with SMI‐4a (n = 6; 60 mg/kg; Selleck Chemicals) or vehicle control (n = 6; 0.1% DMSO/30% PEG-400/0.5% Tween80) once daily for 14 consecutive days after immunization^{65 (link)}. For the in vitro experiments, 20 μM SMI-4a was used.
The mice were intravenously injected with anti-CD20 antibody (n = 6; 250 μg/mouse; Biolegend, San Diego, CA, USA) or an equivalent volume of vehicle control (n = 6; PBS) before (7 days before immunization, day −7) and after EAU development (7 days after immunization, day +7)^{35 (link)}.

Li H., Xie L., Zhu L., Li Z., Wang R., Liu X., Huang Z., Chen B., Gao Y., Wei L., He C., Ju R., Liu Y., Liu X., Zheng Y, & Su W. (2022). Multicellular immune dynamics implicate PIM1 as a potential therapeutic target for uveitis. Nature Communications, 13, 5866.

+ Open protocol

+ Expand

Anti-CD20 Antibody Mediated B Cell Depletion

Check if the same lab product or an alternative is used in the 5 most similar protocols

Wild-type (WT) mice were injected once intraperitoneally with anti-CD20 antibody (BioLegend; Clone: SA271G2; Cat.#152104; 1 mg/mL). Mice were injected between 21 and 28 days of age (100 μL/mouse). Littermate control mice were injected with isotype control antibody (BioLegend; Clone: RTK4530; Cat# 400644). All mice were analyzed 7 days post-injection. B cell depletion was assessed by flow cytometry (Sup. Figure 1).

Rocha-Resende C., Pani F, & Adamo L. (2021). B cells modulate the expression of MHC-II on cardiac CCR2− macrophages. Journal of molecular and cellular cardiology, 157, 98-103.

+ Open protocol

+ Expand

Depleting B and T Cells in SARS-CoV-2 Challenge

Check if the same lab product or an alternative is used in the 5 most similar protocols

All CD20+ B and CD8+ T cell depletion studies followed by wild-type SARS-CoV-2 challenge were carried out by adapting a previously published approach. B cells were depleted from hACE2 transgenic mice through the intraperitoneal (i.p.) administration of 50 μg of anti-CD20 antibody (BioLegend SA271G2) at 72 h (−3 days) and 24 h (−1 day) before vaccination with LUNAR-COV19. For CD8+ T cell depletion, 5 μg of anti-CD8⁺ antibody (Bio X Cell, Cat#BE0061) was injected i.p. at −3 days and −1 day before challenge with SARS-CoV-2. For control mice, isotype IgG2b mouse control antibody (Bio X Cell, Cat#BE0090) was similarly injected. Successful depletions of CD20⁺ B and/or CD8⁺ T cells were confirmed via flow cytometry. Briefly, 24 h after the second injection of anti-CD20⁺ and/or anti-CD8⁺ antibodies, sub-mandibular blood was stained with AF488-conjugated anti-mouse CD45R (BD, Cat#557669), APC-conjugated anti-mouse CD3 (BD, Cat#565643), and BUV395-conjugated anti-mouse CD8b antibodies (BD, Cat#74027).

de Alwis R., Gan E.S., Chen S., Leong Y.S., Tan H.C., Zhang S.L., Yau C., Low J.G., Kalimuddin S., Matsuda D., Allen E.C., Hartman P., Park K.J., Alayyoubi M., Bhaskaran H., Dukanovic A., Bao Y., Clemente B., Vega J., Roberts S., Gonzalez J.A., Sablad M., Yelin R., Taylor W., Tachikawa K., Parker S., Karmali P., Davis J., Sullivan B.M., Sullivan S.M., Hughes S.G., Chivukula P, & Ooi E.E. (2021). A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. Molecular Therapy, 29(6), 1970-1983.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!